NKTX - NASDAQ
Nkarta, Inc.
$2.77
-12%Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
At a Glance
Live Snapshotnktx
Selling, General and Administrative Expenses
Last Annual Value
31.57M
3-Year CAGR
4%
5-Year CAGR
16%
10-Year CAGR
28%
Nkarta, Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Nkarta, Inc. NASDAQ:NKTX | 31.57M | -3.3% | 6.5% | N/A | |
 Forte Biosciences, Inc. NASDAQ:FBRX | 12.41M | 5.3% | 10.2% | 11.3% | |
 Alector, Inc. NASDAQ:ALEC | 53.99M | -1.6% | -0.4% | 39.9% | |
 Fate Therapeutics, Inc. NASDAQ:FATE | 46.52M | -21.7% | -4.1% | 16.7% | |
 Vor Biopharma Inc. NASDAQ:VOR | 50.11M | 16.5% | 18.5% | N/A | |
 Actuate Therapeutics Inc NASDAQ:ACTU | 12.20M | 55.2% | N/A | N/A | |
 Seres Therapeutics, Inc. NASDAQ:MCRB | 39.16M | -20.4% | -10.8% | 1.8% | |
 Tonix Pharmaceuticals Holding Corp. NASDAQ:TNXP | 87.68M | 36.1% | 30.2% | 23.7% | |
 Elicio Therapeutics, Inc. NASDAQ:ELTX | 12.81M | 2.5% | -6.3% | N/A | |
 Applied Therapeutics, Inc. NASDAQ:APLT | 56.01M | 39.5% | 5.4% | N/A | |
 PepGen Inc. NASDAQ:PEPG | 22.57M | 10.7% | 22.7% | N/A |
Nkarta, Inc. Fair Value Envelope
Related Guides
Continue your NKTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.